Wearable flexible electronic strain sensor devices have developed rapidly in recent years due to their potential capacity to detect human motion in various situations. However, it still remains still a big challenge to fabricate strain sensors with high sensitivity over a wide workable strain range. In order to meet this challenge, a new type of strain sensor based on elastomer/carbon nanotube composite fiber is reported in this work. Elastomer fibers are initially prepared via the electrospinning of styrene ethylene butene styrene block copolymer (SEBS). The resultant SEBS fibers are then functionalized by sequentially coating with dopamine (DA) coating and carboxyl group (‐COOH) grafted multi‐walled carbon nanotubes (MWCNTs) under vacuum filtration and ultrasonication. Scanning electron microscopy (SEM) and thermogravimetric analysis reveals that a large amount of MWCNTs is firmly bonded onto the SEBS fibers and evenly distributed. SEBS@PDA/MWCNTs composite fibers based strain sensors exhibit excellent performance, including a high gauge factor of 3717 and large workable strain range up to 530%. Furthermore, the developed sensors demonstrate excellent washing fastness and superior sensitivity in monitoring both small strains (e.g., pulse beats and vocal cord vibrations) and large strains (e.g., finger, elbow, and knee bending).

BackgroundSeveral studies have investigated the value of the systemic immune-inflammation index (SII) for predicting cardiovascular disease (CVD), but the results were inconsistent. Therefore, a meta-analysis and systematic review were conducted to assess the correlation between SII and risk of CVD.Materials and methodsTwo investigators systematically searched PubMed, Embase, Web of Science, Cochrane library, and CINAHL databases to identify all studies that examined the association between SII levels and CVD. The risk estimates of CVD for people with high SII compared to those with low SII levels and the weighted mean difference (WMD) between the CVD and control groups were pooled using fixed- or random-effects models based on the heterogeneity test. We used the Newcastle-Ottawa Scale to assess the risk of bias in eligible studies, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was applied to rate the certainty of evidence.ResultsA total of 13 studies with 152,996 participants were included for analysis. The overall pooled results showed that higher SII was significantly associated with an increased risk of CVD (HR = 1.39, 95%CI: 1.20–1.61, P < 0.001). This increased risk could be observed in almost all CVD subtypes, including ischemic stroke (HR = 1.31, 95%CI: 1.06–1.63, P = 0.013), hemorrhagic stroke (HR = 1.22, 95%CI: 1.10–1.37, P < 0.001), myocardial infarction (HR = 1.11, 95%CI: 1.01–1.23, P = 0.027), and peripheral arterial disease (HR = 1.51, 95%CI: 1.18–1.93, P = 0.001). There were no significant but still similar trends in venous thrombosis (HR = 4.65, 95%CI: 0.66–32.71, P = 0.122), cerebral small vessel disease (HR = 1.09, 95%CI: 0.95–1.25, P = 0.233), and acute coronary syndrome (HR = 1.08, 95%CI: 0.96–1.22, P = 0.200). Furthermore, the pooled results showed that SII levels at the onset of CVD were significantly higher than that in the general population (WMD = 355.2, 95%CI: 234.8–475.6, P < 0.001), which was consistent across different CVD subtypes. The GRADE assessment suggested that the quality of current evidence from observational studies was low or very low.ConclusionThis study indicated that SII may be a potential biomarker for CVD development and elevated SII is associated with an increased risk of CVD. However, the quality of evidence is generally low. Additional well-designed studies are necessary to determine the optimal cutoff value and to characterize the benefited population.

No abstract

No abstract